PRAsugrel or clopIdogrel In Acute Coronary SyndromE With CYP2C19 GENEtic Variants

• Status: Completed
• Trial end date: 2019-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators hypothesize that reduced loading dose of prasugrel followed by reduced maintenance dose of prasugrel in acute coronary syndrome patients with CYP2C19 polymorphism undergoing percutaneous coronary intervention might exhibit lower platelet reactivity 24 hours and 30 days later which is associated with major adverse cardiovascular events.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dong-A University
• Treatments: Clopidogrel; Prasugrel Hydrochloride; Ticlopidine

Criteria

Inclusion Criteria:

• Acute coronary syndrome

• Patients planned to undergo percutaneous transluminal coronary angioplasty

• Patients who agreed to the experimental plan which was permitted by IRB

Exclusion Criteria:

• Low body weight (< 50kg)

• History of stroke or transient ischemic attack

• History of upper gastrointestinal bleeding in recent 6 months

• Renal dysfunction defined by serum creatinine > 2.5 mg/dl

• Severe hepatic dysfunction defined by Child-Pugh criteria B or C

• Bleeding tendency

• Anticoagulation treatment including warfarin

• Thrombocytopenia defined by platelet < 100,000/ml

• Anemia defined by hemoglobin < 10 g/dl

• Contraindication for antiplatelet treatment or anticoagulation treatment

• History of administer glycoprotein IIb/IIIa inhibitor in recent 24hrs or planned to